B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade - PubMed
- ️Tue Jan 01 2013
B cell responses to HIV antigen are a potent correlate of viremia in HIV-1 infection and improve with PD-1 blockade
Katherine J Nicholas et al. PLoS One. 2013.
Abstract
Infection with Human Immunodeficiency Virus Type 1 (HIV-1) induces defects of both cellular and humoral immune responses. Impaired CD4+ T cell help and B cell dysfunction may partially explain the low frequency of broadly neutralizing antibodies in HIV-infected individuals. To understand the extent of B cell dysfunction during HIV infection, we assessed the level of B cell activation at baseline and after stimulation with a variety of antigens. Increased levels of viremia were associated with higher baseline expression of the activation marker CD86 on B cells and with decreased ability of B cells to increase expression of CD86 after in vitro stimulation with inactivated HIV-1. In a series of cell isolation experiments B cell responses to antigen were enhanced in the presence of autologous CD4+ T cells. HIV infected individuals had a higher frequency of PD-1 expression on B cells compared to HIV- subjects and PD-1 blockade improved B cell responsiveness to HIV antigen, suggesting that inhibitory molecule expression during HIV-1 infection may contribute to some of the observed B cell defects. Our findings demonstrate that during chronic HIV infection, B cells are activated and lose full capacity to respond to antigen, but suppression of inhibitory pressures as well as a robust CD4+ T cell response may help preserve B cell function.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures

PBMCs from HIV- (open circles) or HIV+ (closed circles) subjects were incubated overnight without stimulation and evaluated for surface level CD86 expression on B cells. HIV+ subjects had a higher frequency of CD86+ B cells compared to HIV- subjects (unpaired t-test not shown on graph, p=0.03). The frequency of CD19+CD86+ B cells in HIV+ individuals correlates with the level of viremia (r=.63; p=.003). Correlation statistics shown are derived from HIV+ subject data only and do not include data from HIV- subjects.

PBMCs were cultured overnight with or without anti-CD3 stimulation. Change in CD25 or CD86 expression was determined by subtracting the frequency of expression before stimulation from the frequency of expression after stimulation. (A) Representative plots of CD25 expression on CD4+ T cells and B cells with (bottom) and without (top) anti-CD3 stimulation. CD4+ T cell population shown is CD3+CD4+CD19- and B cell population shown is CD3-CD4-CD19+. (B-D) Change in expression of CD25 on CD4+ T cells (r= -.53; p= .056) (B), CD25 on B cells (r= -.63; p= .018) (C), and CD86 on B cells (r= -.44; p= .11) (D) correlates negatively with viral load.

(A) Expression of CD86 on B cells after stimulation of PBMC with HIV-1 MN control (left column) or HIV-1 MN (right column). Shown are representative plots from one individual (subject 10071).. (B) PBMCs from 21 HIV-infected individuals (closed circles) and 7 HIV-negative control subjects (open circles) were incubated with inactivated HIV-1 MN, and changes in CD86 expression on B cells were measured. Change was calculated by subtracting the frequency of CD86 expression from stimulation with the HIV-1 MN control (containing no HIV proteins) from stimulation with HIV-1 MN. CD86 expression on B cells in response to HIV-antigen in HIV infected individuals is negatively correlated with viral load (r= -.6; p= .006). Correlation statistics are only applied to HIV-infected individuals and do not include data from uninfected subjects.

Change in the frequency of CD86+ B cells in response to SEB (A) or HIV p24 antigen (B) was evaluated in total PBMC culture, purified B cell culture, or purified B cells co-cultured with autologous purified CD4+ T cells.

Expression of PD-1 on B cells, CD4+ T cells, and CD8+ cells was measured directly ex vivo. (A) In HIV-infected individuals, PD-1 expression on CD4+ is not correlated with viral load (r=.33; p=.17). (B) In HIV-infected individuals PD-1 expression on CD8+ T cells correlated positively with viral load (r= .56; p=.01). (C) PD-1 expression is higher on B cells from HIV+ (closed circles) compared to HIV- (open circles) subjects (p=.04). (D) The frequency of PD-1 surface expression is significantly lower on B cells compared to CD4 (p< .0001) and CD8 T cells (p<.0001) in HIV infection.

PBMCs were cultured overnight with or without anti-PD-1 and stimulated with inactivated HIV-1 MN protein. Change in response to MN stimulation was calculated by subtracting stimulation with MN control protein from stimulation with HIV-1 MN protein (p= .003).
Similar articles
-
Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function.
Malaspina A, Moir S, Kottilil S, Hallahan CW, Ehler LA, Liu S, Planta MA, Chun TW, Fauci AS. Malaspina A, et al. J Immunol. 2003 Jun 15;170(12):5965-72. doi: 10.4049/jimmunol.170.12.5965. J Immunol. 2003. PMID: 12794123
-
Porichis F, Hart MG, Zupkosky J, Barblu L, Kwon DS, McMullen A, Brennan T, Ahmed R, Freeman GJ, Kavanagh DG, Kaufmann DE. Porichis F, et al. J Virol. 2014 Mar;88(5):2508-18. doi: 10.1128/JVI.02034-13. Epub 2013 Dec 18. J Virol. 2014. PMID: 24352453 Free PMC article.
-
Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.
Tripiciano A, Picconi O, Moretti S, Sgadari C, Cafaro A, Francavilla V, Arancio A, Paniccia G, Campagna M, Pavone-Cossut MR, Sighinolfi L, Latini A, Mercurio VS, Pietro MD, Castelli F, Saracino A, Mussini C, Perri GD, Galli M, Nozza S, Ensoli F, Monini P, Ensoli B. Tripiciano A, et al. EBioMedicine. 2021 Apr;66:103306. doi: 10.1016/j.ebiom.2021.103306. Epub 2021 Apr 7. EBioMedicine. 2021. PMID: 33839064 Free PMC article.
-
Boliar S, Murphy MK, Tran TC, Carnathan DG, Armstrong WS, Silvestri G, Derdeyn CA. Boliar S, et al. J Virol. 2012 Aug;86(15):8031-40. doi: 10.1128/JVI.00771-12. Epub 2012 May 23. J Virol. 2012. PMID: 22623771 Free PMC article. Clinical Trial.
-
B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.
Cagigi A, Nilsson A, De Milito A, Chiodi F. Cagigi A, et al. Vaccine. 2008 Jun 6;26(24):3016-25. doi: 10.1016/j.vaccine.2007.11.063. Epub 2007 Dec 17. Vaccine. 2008. PMID: 18164520 Review.
Cited by
-
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z. Jiang X, et al. Mol Cancer. 2019 Jan 15;18(1):10. doi: 10.1186/s12943-018-0928-4. Mol Cancer. 2019. PMID: 30646912 Free PMC article. Review.
-
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
O'Neill RE, Cao X. O'Neill RE, et al. Adv Cancer Res. 2019;143:145-194. doi: 10.1016/bs.acr.2019.03.003. Epub 2019 Apr 17. Adv Cancer Res. 2019. PMID: 31202358 Free PMC article. Review.
-
Sullivan RT, Kim CC, Fontana MF, Feeney ME, Jagannathan P, Boyle MJ, Drakeley CJ, Ssewanyana I, Nankya F, Mayanja-Kizza H, Dorsey G, Greenhouse B. Sullivan RT, et al. PLoS Pathog. 2015 May 19;11(5):e1004894. doi: 10.1371/journal.ppat.1004894. eCollection 2015 May. PLoS Pathog. 2015. PMID: 25993340 Free PMC article.
-
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Ohaegbulam KC, et al. Trends Mol Med. 2015 Jan;21(1):24-33. doi: 10.1016/j.molmed.2014.10.009. Epub 2014 Oct 30. Trends Mol Med. 2015. PMID: 25440090 Free PMC article. Review.
-
Nicholas KJ, Flaherty DK, Smith RM, Sather DN, Kalams SA. Nicholas KJ, et al. J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):72-80. doi: 10.1097/QAI.0000000000001152. J Acquir Immune Defic Syndr. 2017. PMID: 27509243 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous